| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Cysteamine S-phosphate sodium is a prodrug of cysteamine. Its primary target is not a receptor or enzyme itself, but rather it is hydrolyzed to release the active molecule cysteamine. Cysteamine is an orally bioactive molecule used for the treatment of nephropathic cystinosis and also functions as an antioxidant. By providing a phosphate-protected form of cysteamine, this compound may offer improved stability or delivery properties.
|
|---|---|
| ln Vitro |
In vitro, Cysteamine S-phosphate sodium can be hydrolyzed to cysteamine by human alkaline phosphatase. Cysteamine, the active product, is an antioxidant and is used for the research of nephropathic cystinosis. Specific activity data for the parent compound are not applicable as it is a prodrug.
|
| ln Vivo |
In vivo, Cysteamine S-phosphate sodium is a prodrug that releases cysteamine, which is used for the treatment of nephropathic cystinosis. Cysteamine is an orally active agent. The phosphate salt form may enhance the solubility and stability of the compound for administration. Specific in vivo efficacy data for Cysteamine S-phosphate sodium are not detailed in the available sources.
|
| Enzyme Assay |
A cell-free assay for Cysteamine S-phosphate sodium would involve measuring its hydrolysis by alkaline phosphatase. In this assay, the compound is incubated with alkaline phosphatase, and the release of cysteamine is measured. Alternatively, the compound can be used as an analytical standard for the quantification of cysteamine in biological samples.
|
| Cell Assay |
Cellular experiments with Cysteamine S-phosphate sodium are not typical, as it is a prodrug and its effects are mediated through the release of cysteamine. Cysteamine's effects on cellular redox status and cystine accumulation can be studied in cell culture models of cystinosis.
|
| Animal Protocol |
In vivo animal experiments for Cysteamine S-phosphate sodium are not described in the available sources. As a prodrug of cysteamine, it could be evaluated in animal models of cystinosis to assess its efficacy in reducing cystine accumulation. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
Cysteamine S-phosphate sodium has a molecular formula of C2H7NNaO3PS and a molecular weight of 179.11 g/mol. Its CAS number is 3724-89-8. It is a solid. For storage, it should be kept at 2-8°C. Specific pharmacokinetic properties are not provided in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicity data for Cysteamine S-phosphate sodium are not provided in the available sources. As a prodrug of cysteamine, its safety profile is likely similar to that of cysteamine, which is used clinically. However, specific toxicological information is not available. It is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
It is intended as an adjuvant drug for cancer chemotherapy; it may also have radiation protection effects.
Cysteamine S-phosphate sodium (CAS: 3724-89-8) is a phosphate-protected form of cysteamine. It is also known as Cystaphos sodium. The compound is hydrolyzed to cysteamine by alkaline phosphatase. Cysteamine is used for the treatment of nephropathic cystinosis and as an antioxidant. This compound is used in research and as an analytical standard. |
| Molecular Formula |
C2H7NO3PS-.NA+
|
|---|---|
| Molecular Weight |
179.11048
|
| Exact Mass |
178.978
|
| CAS # |
3724-89-8
|
| PubChem CID |
23664253
|
| Appearance |
White to off-white solid powder
|
| Density |
1.597g/cm3
|
| Boiling Point |
384.2ºC at 760mmHg
|
| Melting Point |
220ºC (dec.)(lit.)
|
| Flash Point |
186.2ºC
|
| LogP |
0.909
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
112
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na+].NCCSP([O-])(O)=O
|
| InChi Key |
VZEGNYNPDZDIRW-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C2H8NO3PS.Na/c3-1-2-8-7(4,5)6;/h1-3H2,(H2,4,5,6);/q;+1/p-1
|
| Chemical Name |
sodium;2-aminoethylsulfanyl(hydroxy)phosphinate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5832 mL | 27.9158 mL | 55.8316 mL | |
| 5 mM | 1.1166 mL | 5.5832 mL | 11.1663 mL | |
| 10 mM | 0.5583 mL | 2.7916 mL | 5.5832 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
